Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | CLIMB360: ctDNA-based molecular screening

Javier Garcia-Corbacho • 13 Sep 2021
ESMO 2021
General

Javier Garcia-Corbacho, MD, Hospital Clinic Barcelona, Barcelona, Spain, discusses the first results of the CLIMB360 study, a prospective molecular screening program accross multiple cancer types based on circulating tumor DNA (ctDNA). In this study it was found that real-time and prospective genomic profiling of patients with advanced cancer using ctDNA is feasible, fast and helps to identify therapeutic targets approved or evaluated in clinical trials. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

Disclosures

Dr Garcia-Corbacho declares participation in multiple clinical trials and meetings as speaker (advisory role) and financial sponsor support for meeting attendance.

More from Javier Garcia-Corbacho

0:46
The potential of ctDNA in oncology
Javier Garcia-Corbacho • 13 Oct 2021

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals